Columbia Laboratories Announces Issuance of Patent Covering Drug Delivery Technology for Use in the Prevention of Sexually Transmitted Diseases.MIAMI--(BW HealthWire)--Sept. 19, 1997--Columbia Laboratories Inc. (ASE (Adaptive Server Enterprise) A relational DBMS from Sybase that runs on Windows NT/2000, Linux and a variety of Unix platforms. ASE is a comprehensive and robust data management product with a long history dating back to the late 1980s. :COB) Friday announced the issuance of U.S. Patent No. 5,667,492 covering the technology used in its product Advantage 24(tm), which potentiates the activity of nonoxynol-9 against various organisms which can cause sexually transmitted disease sexually transmitted disease (STD) or venereal disease, term for infections acquired mainly through sexual contact. Five diseases were traditionally known as venereal diseases: gonorrhea, syphilis, and the less common granuloma inguinale, ("STD (Subscriber Trunk Dialing) Long distance dialing outside of the U.S. that does not require operator intervention. STD prefix codes are required and billing is based on call units, which are a fixed amount of money in the currency of that country. "), including AIDS, gonorrhea, chlamydia and trichomonal trichomonal pertaining to trichomonads. trichomonal enteritis the cause-and-effect relationship between the numbers of trichomonads found in association with enteric disease, especially colitis in horses, is doubtful. infections, syphilis and genital herpes. The Columbia Bioadhesive Delivery System enables Advantage 24 to adhere to the cervix and vaginal epithelium and slowly release nonoxynol-9 for an extended period for as much as 48 to 72 hours. Since the technology enables the use of relatively low amounts of nonoxynol-9, irritation to the genital tissue is minimized. Advantage 24 is currently being tested under an IND filed with the FDA to evaluate its efficacy in the prevention of STD's. In addition, under the supervision of the Joint United Nations Programme on HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (UNAIDS), Advantage 24 has been tested for safety in more than 600 women in Europe and Thailand. These studies showed that Advantage 24, unlike many other anti-STD formulations tested by UNAIDS, was safe even when administered four times a day. Because of these factors, Advantage 24 is the only product that UNAIDS has selected for testing for the prevention of the heterosexual transmission of sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely and the human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. (HIV), in approximately 2,000 women. Advantage 24 is currently marketed in the United States and Canada under several licensing agreements. Columbia Laboratories Inc. is a U.S.-based international pharmaceutical company, dedicated to the development of women's prescription and over-the-counter products, including those which help prevent sexually transmitted diseases. Columbia's products primarily utilize the company's patented bioadhesive delivery system. CONTACT: Columbia Laboratories Inc., Miami David L. Weinberg, Chief Financial Officer 305/860-1692 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion